<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" xml:lang="en" dtd-version="1.4"><!--The publisher of this article does not allow downloading of the full text in XML form.--><front><journal-meta><journal-id journal-id-type="nlm-ta">Cancer Immunol Immunother</journal-id><journal-id journal-id-type="iso-abbrev">Cancer Immunol Immunother</journal-id><journal-id journal-id-type="pmc-domain-id">4569</journal-id><journal-id journal-id-type="pmc-domain">cii</journal-id><journal-title-group><journal-title>Cancer Immunology, Immunotherapy : CII</journal-title></journal-title-group><issn pub-type="ppub">0340-7004</issn><issn pub-type="epub">1432-0851</issn><publisher><publisher-name>Springer</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC11036988</article-id><article-id pub-id-type="pmcid-ver">PMC11036988.1</article-id><article-id pub-id-type="pmcaid">11036988</article-id><article-id pub-id-type="pmcaiid">11036988</article-id><article-id pub-id-type="pmid">10782866</article-id><article-id pub-id-type="doi">10.1007/s002620050026</article-id><article-id pub-id-type="publisher-id">00490056.262</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>Phase I trial of interleukin-2 and high-dose arginine butyrate in metastatic colorectal cancer</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Douillard</surname><given-names initials="JY">J. Y.</given-names></name><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Bennouna</surname><given-names initials="J">J.</given-names></name><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Vavasseur</surname><given-names initials="F">F.</given-names></name><xref ref-type="aff" rid="A2">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Deporte-Fety</surname><given-names initials="R">R.</given-names></name><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Thomare</surname><given-names initials="P">P.</given-names></name><xref ref-type="aff" rid="A3">3</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Giacalone</surname><given-names initials="F">F.</given-names></name><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Meflah</surname><given-names initials="K">K.</given-names></name><xref ref-type="aff" rid="A2">2</xref></contrib><aff id="A1"><label/><institution-wrap><institution-id institution-id-type="GRID">grid.418191.4</institution-id><institution-id institution-id-type="ISNI">0000000094373027</institution-id><institution>Centre Ren&#233; Gauducheau, CRLCC Nantes-Atlantique, F-44805 Saint-Herblain Cedex, France e-mail: s-scientifique@nantes.fnclcc.fr Tel.: +33-2-40-67-99-78 Fax: +33-2-40-67-97-09, </institution></institution-wrap>, , , FR </aff><aff id="A2"><label/>U419 INSERM, F-44000 Nantes, France, , , , FR </aff><aff id="A3"><label/>CHU, Nantas, France, , , , FR </aff></contrib-group><pub-date pub-type="ppub"><month>03</month><year>2000</year></pub-date><volume>49</volume><issue>1</issue><issue-id pub-id-type="pmc-issue-id">460665</issue-id><fpage>56</fpage><lpage>61</lpage><pub-history><event event-type="pmc-release"><date><day>01</day><month>03</month><year>2000</year></date></event><event event-type="pmc-live"><date><day>25</day><month>04</month><year>2024</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2024-04-26 00:25:14.410"><day>26</day><month>04</month><year>2024</year></date></event></pub-history><permissions><copyright-statement>&#169; Springer-Verlag Berlin Heidelberg 2000</copyright-statement></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="262_2000_Article_490056.262.pdf"/><abstract id="Abs1"><title>Abstract Introduction:</title><p> Interleukin-2 (IL-2) and sodium butyrate allow rats to be cured of peritoneal carcinomatosis from colon cancer. We performed a phase I trial of IL-2 and high-dose arginine butyrate (ArgB) in patients with advanced metastatic colorectal cancer. <bold>Patients and methods:</bold> From April to July 1997, six patients were included in the trail; they had a median age of 52 years, four had a performance status of 0, two had a performance status of 1 with normal biological functions. All patients had received at least two prior lines of chemotherapy. A fixed dose of 18&#8201;MIU/m<sup>2</sup> IL-2,was administered by subcutaneous injection and ArgB was delivered via continuous intravenous infusion on days 1&#8211;6 with escalating doses starting at 2&#8201;g&#8201;kg<sup>&#8722;1</sup>&#8201;day<sup>&#8722;1</sup>. <bold>Results:</bold> The planned dose escalation was not possible because of toxicities. A daily ArgB dose of 2&#8201;g/kg was delivered for nine cycles. Level 2 (4&#8201;g/kg) could not be delivered in three of the six patients because of liver toxicity. The dose-limiting toxicities were fatigue and liver function disturbances. The maximum tolerated dose for ArgB was 3&#8201;g&#8201;kg<sup>&#8722;1</sup>&#8201;day<sup>&#8722;1</sup>, in combination with IL-2&#8201;at 12&#8201;MIU&#8201;m<sup>2</sup>&#8201;day<sup>&#8722;1</sup>. No clinical response was seen. Pharmacokinetic analysis showed large intra- and interindividual variations. <bold>Conclusion:</bold> This schedule with a high dose of ArgB proved to be highly toxic with liver insufficiency. We will be running another trial with lower doses of ArgB calculated from the schedule used in the experimental model, starting at a dose of 20&#8201;mg kg<sup>&#8722;1</sup>&#8201;day<sup>&#8722;1</sup> for ArgB and 200 000 UI kg<sup>&#8722;1</sup>&#8201;day<sup>&#8722;1</sup> IL-2, every 8 h.</p></abstract><kwd-group xml:lang="en"><kwd>Key words&#8194;Apoptosis</kwd><kwd>Immune stimulation</kwd><kwd>Cell differentiation</kwd><kwd>IL-2</kwd><kwd>Arginine butyrate</kwd><kwd>Colorectal cancer</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#169; Springer-Verlag Berlin Heidelberg 2000</meta-value></custom-meta></custom-meta-group></article-meta></front></article></pmc-articleset>